Clinical Topics   /   Pharmacy

New SGLT2 Inhibitor Approved to Treat Type 2 Diabetes

By U.S. Medicine

WASHINGTON A new sodium-glucose co-transporter 2 (SGLT2) inhibitor has been approved to treat type 2 diabetes.

The Food and Drug Administration approved Farxiga (dapaglifozin) tablets to improve glycemic control, along with diet and exercise, in adults. Farxiga is marketed by Bristol-Myers Squibb Company, Princeton, NJ, and AstraZeneca Pharmaceuticals LP, Wilmington, DE.

Controlling blood sugar levels is very important in the overall treatment and care of diabetes, and Farxiga provides an additional treatment option for millions of Americans with type 2 diabetes,” said Curtis Rosebraugh, MD, MPH, director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research.

SGLT2 inhibitors block the reabsorption of glucose by the kidney, increase glucose excretion and lower blood glucose levels.

Farxiga’s safety and effectiveness were evaluated in 16 clinical trials involving more than 9,400 patients with type 2 diabetes. The drug was shown to improve patients HbA1c measurements.

The studies involved Farxiga both as a monotherapy and in combination with other type 2 diabetes medications, including metformin, pioglitazone, glimepiride, sitagliptin and insulin.

The FDA noted that Farxiga should not be used to treat people with type 1 diabetes, diabetic ketoacidosis or moderate or severe renal impairment, end stage renal disease or who are on dialysis.

Because an increased number of bladder cancers were diagnosed among Farxiga users in clinical trials, the FDA also does not recommend Farxiga is not recommended for patients with active bladder cancer and suggests that patients with a history of bladder cancer talk to their physician before initiation of the therapy.

Farxiga can cause dehydration, leading to hypotension that can result in dizziness and/or fainting and a decline in renal function. The elderly, patients with impaired renal function and patients on diuretics to treat other conditions appeared to be more susceptible to this risk, the FDA said.

Six post-marketing studies are being required for Farxiga.

Genital mycotic (fungal) infections and urinary tract infections are among the drug’s side effects.


Related Articles

VA Patients Lack Testing to Optimize CLL Treatment

SALT LAKE CITY — The presence of deletion 17p (del17), determined by chromosome analysis and/or fluorescence in situ hybridization (FISH), is a strong negative prognostic marker in chronic lymphocytic leukemia (CLL), according to a report in the Journal of Clinical Oncology.1

Lobectomy Still Has Significant Survival Benefit in Early NSCLC

While increased use of stereotactic body radiation might have played a key role in doubling survival rates for early-stage non-small cell lung cancer (NSCLC) among veterans between 2001 and 2010 compared to conventional radiation, a new study confirms that isn’t always the best way to assure longer survival.


U.S. Medicine Recommends


More From oncology

Oncology

VA Patients Lack Testing to Optimize CLL Treatment

SALT LAKE CITY — The presence of deletion 17p (del17), determined by chromosome analysis and/or fluorescence in situ hybridization (FISH), is a strong negative prognostic marker in chronic lymphocytic leukemia (CLL), according to a report in the Journal of Clinical Oncology.1

Oncology

Lobectomy Still Has Significant Survival Benefit in Early NSCLC

While increased use of stereotactic body radiation might have played a key role in doubling survival rates for early-stage non-small cell lung cancer (NSCLC) among veterans between 2001 and 2010 compared to conventional radiation, a new study confirms that isn’t always the best way to assure longer survival.

Oncology

Gene Assay Can Help Determine Active Surveillance Usefulness

BRONX, NY — For patients with chronic kidney disease (CKD), living more than 30 miles from their nephrologist is associated with many unfavorable outcomes. They have lower rates of clinic visit adherence, more limited access... View Article

Breast Cancer

Chemotherapy Use Declines for Breast Cancer Patients

With growing concern about overtreatment of breast cancer as outcomes have improved over time, not much research has been performed on how chemotherapy use and oncologists' recommendations have changed in recent years.

Oncology

Laparoscopic, Robotic Surgeries Equivalent for Pancreatic Cancer

Pancreatic cancer patients increasingly are receiving minimally invasive pancreaticoduodenectomy (MIPD).

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up